+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party



Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party



New England Journal of Medicine 333(25): 1662-1669



The reverse-transcriptase inhibitor lamivudine has in vitro synergy with zidovudine against the human immunodeficiency virus (HIV). We studied the activity and safety of lamivudine plus zidovudine as compared with either drug alone as treatment for patients with HIV infection, most of whom had not previously received zidovudine. Three hundred sixty-six patients with 200 to 500 CD4+ cells per cubic millimeter who had received zidovudine for four weeks or less were randomly assigned to treatment with one of four regimens: 300 mg of lamivudine every 12 hours; 200 mg of zidovudine every 8 hours; 150 mg of lamivudine every 12 hours plus zidovudine; or 300 mg of lamivudine every 12 hours plus zidovudine. The study was double-blind and lasted 24 weeks, with an extension phase for another 28 weeks. Over the 24-week period, the low-dose and high-dose regimens combining lamivudine and zidovudine were associated with greater increases in the CD4+ cell count (P = 0.002 and P = 0.015, respectively) and the percentage of CD4+ cells (P < 0.001 for both) and with greater decreases in plasma levels of HIV-1 RNA (P < 0.001 for both) than was treatment with zidovudine alone. Combination therapy was also more effective than lamivudine alone in lowering plasma HIV-1 RNA levels and increasing the percentage of CD4+ cells (P < 0.001 for all comparisons), and these advantages persisted through 52 weeks. Adverse events were no more frequent with combination therapy than with zidovudine alone. In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-year period and produces more improvement in immunologic and virologic measures than does treatment with either agent alone.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 044865633

Download citation: RISBibTeXText

PMID: 7477218

DOI: 10.1056/nejm199512213332502


Related references

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Annals of Internal Medicine 125(3): 161-172, 1996

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276(2): 111-117, 1996

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276(2): 118-125, 1996

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. New England Journal of Medicine 322(14): 941-949, 1990

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. New England Journal of Medicine 335(15): 1099-1106, 1996

Working parties in 2002 Mammal working party, beach working party, youth section SJOC, geographical working party, insect working party, aquatic animals working party, hover fly project and ornithological working party Werkgroepen 2002 Zoogdierenwerkgroep, strandwerkgroep, SJOC, geografie werkgroep, insectenwerkgroep, waterbeestjeswerkgroep, zweefvliegenproject, vogelwerkgroep. Amoeba. januari; 761: 11-13, 2002

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Aids 13(7): 851-858, 1999

HIV serum RNA levels, CD4 number and clinical outcomes in HIV infected subjects with 200 to 500 CD4 cells per cubic millimeter receiving zidovudine, with or without didanosine. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 268-269, 1997

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients. Journal of Acquired Immune Deficiency Syndromes 38(5): 627-628, 2005

Emergence of dual resistance to zidovudine and lamivudine in clinical HIV-1 isolates from patients receiving zidovudine/lamivudine combination therapy. Antiviral Therapy 3(2): 97-102, 1998

Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. Journal of Acquired Immune Deficiency Syndromes 23(1): 26-34, 2000

Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in antiretroviral naive HIV patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 261, 2002

A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes 27(2): 116-123, 2001

Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection. Pharmacoeconomics 15(Suppl. 1): 67-74, 1999

AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. Aids 14(4): 367-374, 2000